Charts

Over the past 3 months, 4 analysts have published their opinion on Spruce Biosciences (NASDAQ:SPRB) stock. These analysts are typically ...

Baird cut the price target for Petco Health and Wellness Company, Inc. (NASDAQ: WOOF) from $14 to $11. Baird analyst Justin Kleber ...

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the year ended December 31, 2022 and provided corporate updates.

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023 at 2:40 PM ET.

Let’s talk about winning in the stock market. You can make money no matter what the overall economic conditions are – whether stocks go up or down, there will be opportunities to profit by the moves. The key, of course, is understanding when to buy in and when to sell. Every stock will come with the potential for both risk and reward; successful investors know how to balance them. Few stock segments offer a more interesting – and, potentially, more profitable – risk/reward profile than the penny

The Dow Jones closed lower by around 700 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or ...

Gainers Windtree Therapeutics (NASDAQ:WINT) stock increased by 28.8% to $0.22 during Wednesday's pre-market session. The market value ...

A South San Francisco biotech company, hoping to deliver top-line results from key drug studies targeting a genetic hormonal disorder, raised $53.6 million in a private investment in a public entity, or PIPE, deal. For Spruce Biosciences Inc. (NASDAQ: SPRB), the cash from new investors Armistice Capital and 5AM Ventures, as well as from Abingworth, Novo Holdings A/S, HealthCap, RiverVest Venture Partners and Rock Springs Capital, extends its financial runway from first-half 2024 into early 2025.

Gainers Janux Therapeutics (NASDAQ:JANX) stock moved upwards by 27.8% to $22.83 during Thursday's after-market session. The market ...

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that it has entered into a definitive securities purchase agreement for a private placement that is expected to result in gross proceeds of approximately $53.6 million, before deducting offering expenses. The private placement includes participation from new and existing investors, including 5am Ventures, Abingworth, Armistice Capital, HealthCap, Novo Holdings A/S, RiverVest Venture Partners, and Rock Springs Capital.

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the SVB Securities Global Biopharma Conference on February 15, 2023, at 2:20 p.m. ET.

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

Spruce Biosciences's (NASDAQ:SPRB) short percent of float has risen 17.3% since its last report. The company recently reported that ...

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today provided an update on its clinical programs, anticipated upcoming milestones and strategic priorities for advancing tildacerfont in classic congenital adrenal hyperplasia (CAH) and polycystic ovary syndrome (PCOS).

Gainers CinCor Pharma, Inc. (NASDAQ: CINC) rose 140.2% to $28.30 in pre-market trading after AstraZeneca announced plans to buy ...

It's been an up-and-down week for Bay Area life sciences stocks as health care executives start to flow into San Francisco for the 41st annual J.P. Morgan Healthcare Conference.

Gainers Lucira Health (NASDAQ:LHDX) shares rose 29.5% to $0.51 during Friday's after-market session. Lucira Health's trading volume hit ...

U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 700 points on Friday. The Dow traded up 2.14% ...

Gainers Swvl Holdings Corp. (NASDAQ: SWVL) surged 133% to $0.3218. Swvl recently announced the commencement of a strategic review ...

Gainers Spruce Biosciences (NASDAQ:SPRB) stock increased by 85.6% to $2.32 during Friday's regular session. The current volume of 54.1 ...

U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 550 points on Friday. The Dow traded up 1.69% ...

Gainers Spruce Biosciences (NASDAQ:SPRB) stock rose 80.0% to $2.25 during Friday's pre-market session. The market value of their ...

Gainers OncoCyte Corporation (NASDAQ: OCX) rose 89.2% to $0.70 in pre-market trading. Oncocyte, last month, announced an over 40% ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips The final day of trading this week is here and we're starting it off with a look at the biggest pre-market stock movers for Friday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 or $5 million. Do this now.

Spruce Biosciences Inc(NASDAQ: SPRB) andKaken Pharmaceutical Co. Ltdentered into anexclusive licensing ...

Spruce Biosciences & Kaken Pharmaceutical Announce Strategic Partnership & Exclusive Licensing Agreement to Develop Tildacerfont for CAH in Japan

InvestorPlace - Stock Market News, Stock Advice & Trading Tips We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Wednesday The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 or $5 million. Do this now.

Gainers ADC Therapeutics SA (NASDAQ: ADCT) shares rose 36.8% to $4.35 in pre-market trading. ADC Therapeutics and Sobi announced ...

Gainers AcelRx Pharmaceuticals (NASDAQ:ACRX) shares moved upwards by 21.7% to $2.75 during Monday's after-market session. The company's ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips We're beginning the day with a breakdown of the biggest pre-market stock movers traders need to know about on Thursday morning! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 or $5 million. Do this now.

Gainers Fast Radius, Inc. (NASDAQ: FSRD) shares surged 106.3% to close at $0.21 on Wednesday after dipping around 48% on Tuesday. ...

Gainers Fast Radius, Inc. (NASDAQ: FSRD) shares jumped 109% to $0.2115 after dipping around 48% on Tuesday. Fast Radius ...

JMP Securitiesinitiated coverage onSpruce Biosciences, Inc.(NASDAQ: SPRB) with a Market Outperform and aprice ...

Gainers Spruce Biosciences (NASDAQ:SPRB) shares rose 22.9% to $1.29 during Wednesday's regular session. As of 12:30 EST, Spruce ...

Upgrades According to Janney Montgomery Scott, the prior rating for Consolidated Water Co Ltd (NASDAQ:CWCO) was changed from ...

Spruce Biosciences Reports Third Quarter 2022 Financial Results and Provides Corporate Updates

Spruce Biosciences to Participate in November Investor Conferences

Gainers Statera BioPharma (NASDAQ:STAB) stock increased by 64.8% to $0.23 during Thursday's pre-market session. The ...

Gainers Statera Biopharma, Inc. (NASDAQ: STAB) rose 89.4% to $0.2655 in pre-market trading. Statera Biopharma was recently granted ...

Gainers PepGen Inc. (NASDAQ: PEPG) jumped 110.2% to close at $10.93 after the company announced results from its Phase 1 healthy ...

Spruce Biosciences to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the second quarter ended June 30, 2022 and provided corporate updates.

Gainers NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) shares gained 47.5% to settle at $0.8436 on Thursday. Based on the review of ...

Gainers Immix Biopharma (NASDAQ:IMMX) stock moved upwards by 45.4% to $2.69 during Wednesday's after-market session. Today's trading ...

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that company management will participate in two upcoming investor conferences taking place in June.

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that a submitted abstract was accepted for poster presentation at the 104th Annual Meeting of the Endocrine Society (ENDO 2022) taking place June 11-14, 2022, in Atlanta, GA. In a recorded presentation, the company will highlight results from a recent survey of individuals living with congenital adrenal hyperplasia (CAH) to assess their perceptions around glucocorticoid treatment regimens and glucocorticoid-associated side effects.

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the first quarter ended March 31, 2022 and provided corporate updates.

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that company management will participate in two upcoming investor conferences taking place in May.